CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 47 enrolled
Drug / intervention
temozolomide +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00498927
NCT00498927Phase 2Completed
CompareCT.gov

A Phase II Trial of Continuous Low-Dose Temozolomide for Patients With Recurrent Malignant Glioma

Memorial Sloan Kettering Cancer Center·interventional·Posted Jul 11, 2007·Updated Feb 29, 2016

In Brief

A Phase 2 clinical trial evaluating temozolomide, protein expression analysis, and 3 other interventions for Brain and Central Nervous System Tumors. Completed, enrolled 47 participants across 1 site.

Detailed Summary

RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well temozolomide works in treating patients with recurrent glioblastoma multiforme or other malignant glioma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBrain and Central Nervous System Tumors
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI), Weill Medical College of Cornell University, Schering-Plough

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 11, 2007
Enrollment StartJun 1, 2007
Primary CompletionDec 1, 2013
TodayJul 2, 2026
Enrollment to primary: 6.5 yearsPosted 19.0 years ago

Interventions

temozolomidedrug

protein expression analysisgenetic

reverse transcriptase-polymerase chain reactiongenetic

diagnostic laboratory biomarker analysisother

immunoenzyme techniqueother